As a company dedicated to research and innovation, especially in the area of rare diseases, Actelion relies upon strong collaborations with research institutions, healthcare professionals and patient associations who are helping to bring new insights and innovative treatment options to patients.
Our day-to-day business activities include regular contact with healthcare professionals to benefit from their valuable, independent and expert knowledge, derived from their clinical and disease management experience.
The collaborative research and services delivered by these experts in their field has helped advance science, enhance disease awareness and has often led to improved clinical outcomes for patients.
We believe that healthcare professionals and organizations should be fairly compensated for the legitimate expertise and services they provide to Actelion, as well as for their work educating their peers about new medicines and innovations.
Actelion understands that there is a growing expectation that interactions between the company and external groups are not only conducted with integrity but are also transparent. In-line with the Medicines Australia Code of Conduct, Actelion will disclose any transfers of value as defined in the Code. Actelion recognizes that disclosure can raise data privacy concerns and seeks to work with healthcare professionals to ensure that these concerns are addressed.